Business

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a

articleAclarion, Inc.January 6, 20265/company/aclarion-inc/news/aclarion-announces-first-patient-enrollments-110000185
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

About this update from Aclarion, Inc.

[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqjNbxSKpdl2ksI_nXtiLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone ","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY ","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 ","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the company’s pivotal CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial, advancing enrollment progress in the trial.","length":565,"tagName":"p"},{"type":"text","content":"The trial represents a key clinical and commercial catalyst for the company and is intended to support future reimbursement discussions in the U.S. With the latest enrollments by Northwestern and Scripps, four sites have enrolled one or more patients. Seven clinical sites have completed the required regulatory approvals, contracting, training, and study setup, enabling them to begin enrolling patients. These CLARITY sites include Texas Back Institute, University of Miami Health, Advocate Health, Northwestern Medicine, Scripps Health, Keck Medicine of USC, and J...

More updates from Aclarion, Inc.

Northwestern MedicineScripps Healththe companyAclarion, Incchronic low back painCLARITY trialCLARITYCLARITYenrollmentsurgical planningpatientsCompany